Immunoconjugates, compositions for making them, and methods of making and use
An immunoconjugate in which a phosphate-prodrugged DNA minor groove binding agent of formula (I), where X is a nucleophilically displaceable leaving group, is conjugated to an antibody or an antigen binding fragment of an antibody, and compounds that can be used for making such immunoconjugates, and uses of such immunoconjugates.
1. An immunoconjugate wherein a compound of the formula (I)
wherein X is a nucleophilically displaceable leaving group, or a pharmaceutically acceptable salt thereof, is conjugated at the —NH 2 group thereof via a peptidyl linker to an antibody or an antigen binding fragment such antibody.
2. An immunoconjugate according to claim 1 , having a structure according to formula (IIIa)
wherein
AA a and each AA b are independently selected from the group consisting of alanine, β-alanine, γ-aminobutyric acid, arginine, asparagine, aspartic acid, γ-carboxyglutamic acid, citrulline, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, norleucine, norvaline, ornithine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine;
m is 0, 1, 2, 3, 4, or 5;
Y is a spacer moiety;
n is 1, 2, 3, 4, or 5; and
Ab represents the antibody or antigen binding fragment thereof;
or a pharmaceutically acceptable salt thereof.
3. An immunoconjugate according to claim 1 , having a structure according to formula (IIIa′)
wherein
n is 1, 2, 3, 4, or 5; and
Ab represents the antibody or antigen binding fragment thereof;
or a pharmaceutically acceptable salt thereof.
4. An immunoconjugate comprising a compound of the formula (I)
wherein X is a nucleophilically displaceable leaving group, or a pharmaceutically acceptable salt thereof, and wherein the compound of formula (I) is conjugated at the —NH 2 group via a peptidyl linker to an antibody or an antigen binding fragment.
5. A compound having a structure according to formula (II)
wherein
X is a nucleophilically displaceable leaving group;
AA a and each AA b are independently selected from the group consisting of alanine, β-alanine, γ-aminobutyric acid, arginine, asparagine, aspartic acid, γ-carboxyglutamic acid, citrulline, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, norleucine, norvaline, ornithine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine;
m is 0, 1, 2, 3, 4, or 5;
Y is a spacer moiety; and
Z is a reactive functional group capable of conjugation to an antibody;
or a pharmaceutically acceptable salt thereof.
6. A compound according to claim 5 , wherein AA a is selected from the group consisting of citrulline, lysine, aspartic acid, glutamic acid, serine, isoleucine, leucine, and threonine and m is 0, 1, or 2.
7. A compound according to claim 5 , wherein -AA a -[AA b ] m - is a dipeptide selected from the group consisting of Val-Cit, Phe-Cit, Phe-Lys, Val-Lys, Val-Glu, Val-Asp, Val-Ser, and Val-Gly, each dipeptide being recited in the N-to-C direction.
8. A compound according to claim 5 , wherein -Z is —ONH 2 , —SH, —N 3 , or
9. A compound according to claim 5 , wherein Y is selected from the group consisting of
and combinations thereof,
where the subscript q is 0 or 1 independently for each occurrence thereof and the subscript r is 1 to 24 independently for each occurrence thereof.
10. A compound according to claim 5 , having a structure according to formula (IIa)
or a pharmaceutically acceptable salt thereof.
11. A compound according to claim 5 , having a structure selected from the group consisting of formula (IIb)-(IIg):
or a pharmaceutically acceptable salt thereof.
12. A compound according to formula (I)
wherein X is a nucleophilically displaceable leaving group, or a pharmaceutically acceptable salt thereof.